(Q34150018)

English

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Li Shen

1

1 reference

Europe PubMed Central

31 July 2017

Michael Ciesielski

2

1 reference

Europe PubMed Central

31 July 2017

Swathi Ramakrishnan

3

1 reference

Europe PubMed Central

31 July 2017

Kiersten M Miles

4

1 reference

Europe PubMed Central

31 July 2017

Leigh Ellis

5

1 reference

Europe PubMed Central

31 July 2017

Paula Sotomayor

6

1 reference

Europe PubMed Central

31 July 2017

Protul Shrikant

7

1 reference

Europe PubMed Central

31 July 2017

Robert Fenstermaker

8

1 reference

Europe PubMed Central

31 July 2017

Roberto Pili

9

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

27 January 2012

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

7

1 reference

Europe PubMed Central

31 July 2017

1

1 reference

Europe PubMed Central

31 July 2017

e30815

1 reference

Europe PubMed Central

31 July 2017

copyright license

Creative Commons Attribution 4.0 International

27 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Development of a castrate resistant transplant tumor model of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Antitumor cytotoxic T-cell response induced by a survivin peptide mimic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Specific activity of class II histone deacetylases in human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Regulatory T cells in ovarian cancer: biology and therapeutic potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Acetylation and deacetylation of non-histone proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

CD4(+) regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 July 2018

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Deacetylase inhibition promotes the generation and function of regulatory T cells.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Runx-CBFbeta complexes control expression of the transcription factor Foxp3 in regulatory T cells

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0030815

21 January 2018

IL-27 inhibits the development of regulatory T cells via STAT3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 October 2018

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 October 2018

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 October 2018

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267747

28 October 2018

Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22303460

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22303460

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22303460

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22303460

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/22303460

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22303460

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0030815

1 reference

Europe PubMed Central

31 July 2017

2012PLoSO...730815S

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34150018&oldid=1956418782"